Regulation of p53R2 and its role as potential target for cancer therapy

Cancer Letters

Volumn 276, Issue 1, 2009, Pages 1-7

  Wang, Xin ^a   Zhenchuk, Anna ^a   Wiman, Klas G ^a   Albertioni, Freidoun ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Chemotherapy; Leukemia; Nucleoside analogues; p53; p53R2

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; CISPLATIN; CLADRIBINE; CLOFARABINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GEMCITABINE; HYDROXYUREA; MITOCHONDRIAL DNA; MOLECULAR MARKER; PROTEIN P53; RIBONUCLEOTIDE REDUCTASE; TUMOR MARKER; VINCRISTINE;

CANCER THERAPY; COMPETITIVE INHIBITION; DNA REPAIR; DNA SYNTHESIS; DRUG SENSITIVITY; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; SHORT SURVEY;

EID: 60249091269     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.07.019     Document Type: Review

References (59)

1. Reichard P. From RNA to DNA, why so many ribonucleotide reductases?. Science 260 (1993) 1773-1777
2. Chabes A., and Thelander L. Controlled protein degradation regulates ribonucleotide reductase activity in proliferating mammalian cells during the normal cell cycle and in response to DNA damage and replication blocks. J. Biol. Chem. 275 (2000) 17747-17753
3. Thelander L., and Graslund A. Ribonucleotide reductase in mammalian systems. In: Siegel H., and Siegel A. (Eds). Metal Ions in Biological Systems vol. 30 (1994), Morcel Dekker, Inc., New York 493-542
4. Reichard P., Eliasson R., Ingemarson R., and Thelander L. Cross-talk between the allosteric effector-binding sites in mouse ribonucleotide reductase. J. Biol. Chem. 275 (2000) 33021-33026
5. Engstrom Y., Eriksson S., Jildevik I., Skog S., Thelander L., and Tribukait B. Cell cycle-dependent expression of mammalian ribonucleotide reductase. Differential regulation of the two subunits. J. Biol. Chem. 260 (1985) 9114-9116
6. Guittet O., Hakansson P., Voevodskaya N., Fridd S., Graslund A., Arakawa H., Nakamura Y., and Thelander L. Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells. J. Biol. Chem. 276 (2001) 40647-40651
7. Yamaguchi T., Matsuda K., Sagiya Y., Iwadate M., Fujino M.A., Nakamura Y., and Arakawa H. p53R2-dependent pathway for DNA synthesis in a p53-regulated cell cycle checkpoint. Cancer Res. 61 (2001) 8256-8262
8. Tanaka H., Arakawa H., Yamaguchi T., Shiraishi K., Fukuda S., Matsui K., Takei Y., and Nakamura Y. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 404 (2000) 42-49
9. Nakano K., Balint E., Ashcroft M., and Vousden K.H. A ribonucleotide reductase gene is a transcriptional target of p53 and p73. Oncogene 19 (2000) 4283-4289
10. Tsai M.H., Chen X., Chandramouli G.V., Chen Y., Yan H., Zhao S., Keng P., Liber H.L., Coleman C.N., Mitchell J.B., and Chuang E.Y. Transcriptional responses to ionizing radiation reveal that p53R2 protects against radiation-induced mutagenesis in human lymphoblastoid cells. Oncogene 25 (2006) 622-632
11. Xue L., Zhou B., Liu X., Qiu W., Jin Z., and Yen Y. Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits. Cancer Res. 63 (2003) 980-986
12. Liu X., Zhou B., Xue L., Shih J., Tye K., Qi C., and Yen Y. The ribonucleotide reductase subunit M2B subcellular localization and functional importance for DNA replication in physiological growth of KB cells. Biochem. Pharmacol. 70 (2005) 1288-1297
13. Hakansson P., Hofer A., and Thelander L. Regulation of mammalian ribonucleotide reduction and dNTP pools after DNA damage and in resting cells. J. Biol. Chem. 281 (2006) 7834-7841
14. Yanamoto S., Iwamoto T., Kawasaki G., Yoshitomi I., Baba N., and Mizuno A. Silencing of the p53R2 gene by RNA interference inhibits growth and enhances 5-fluorouracil sensitivity of oral cancer cells. Cancer Lett. 223 (2005) 67-76
15. Bourdon A., Minai L., Serre V., Jais J.P., Sarzi E., Aubert S., Chretien D., de Lonlay P., Paquis-Flucklinger V., Arakawa H., Nakamura Y., Munnich A., and Rotig A. Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion. Nat. Genet. 39 (2007) 776-780
16. Chabes A.L., Pfleger C.M., Kirschner M.W., and Thelander L. Mouse ribonucleotide reductase R2 protein: a new target for anaphase-promoting complex-Cdh1-mediated proteolysis. Proc. Natl. Acad. Sci. USA 100 (2003) 3925-3929
17. Zhou B., Liu X., Mo X., Xue L., Darwish D., Qiu W., Shih J., Hwu E.B., Luh F., and Yen Y. The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53. Cancer Res. 63 (2003) 6583-6594
18. Decraene D., Smaers K., Maes D., Matsui M., Declercq L., and Garmyn M. A low UVB dose, with the potential to trigger a protective p53-dependent gene program, increases the resilience of keratinocytes against future UVB insults. J. Invest. Dermatol. 125 (2005) 1026-1031
19. Kimura T., Takeda S., Sagiya Y., Gotoh M., Nakamura Y., and Arakawa H. Impaired function of p53R2 in Rrm2b-null mice causes severe renal failure through attenuation of dNTP pools. Nat. Genet. 34 (2003) 440-445
20. Powell D.R., Desai U., Sparks M.J., Hansen G., Gay J., Schrick J., Shi Z.Z., Hicks J., and Vogel P. Rapid development of glomerular injury and renal failure in mice lacking p53R2. Pediatr. Nephrol. 20 (2005) 432-440
21. Xue L., Zhou B., Liu X., Wang T., Shih J., Qi C., Heung Y., and Yen Y. Structurally dependent redox property of ribonucleotide reductase subunit p53R2. Cancer Res. 66 (2006) 1900-1905
22. Zhou B., Shao J., Su L., Yuan Y.C., Qi C., Shih J., Xi B., Chu B., and Yen Y. A dityrosyl-diiron radical cofactor center is essential for human ribonucleotide reductases. Mol. Cancer Ther. 4 (2005) 1830-1836
23. Shao J., Zhou B., Zhu L., Qiu W., Yuan Y.C., Xi B., and Yen Y. In vitro characterization of enzymatic properties and inhibition of the p53R2 subunit of human ribonucleotide reductase. Cancer Res. 64 (2004) 1-6
24. Yen Y., Chu B., Yen C., Shih J., and Zhou B. Enzymatic property analysis of p53R2 subunit of human ribonucleotide reductase. Adv. Enzyme Regul. 46 (2006) 235-247
25. Nordlund P., and Reichard P. Ribonucleotide reductases. Annu. Rev. Biochem. 75 (2006) 681-706
26. Wei P.P., Tomter A.B., Rohr A.K., Andersson K.K., and Solomon E.I. Circular dichroism and magnetic circular dichroism studies of the active site of p53R2 from human and mouse: iron binding and nature of the biferrous site relative to other ribonucleotide reductases. Biochemistry 45 (2006) 14043-14051
27. Tudzarova-Trajkovska S., and Wesierska-Gadek J. Strong induction of p73 protein in vivo coincides with the onset of apoptosis in rat liver after treatment with the hepatocarcinogen N-nitrosomorpholine (NNM). J. Cell. Biochem. 90 (2003) 837-855
28. Vayssade M., Haddada H., Faridoni-Laurens L., Tourpin S., Valent A., Benard J., and Ahomadegbe J.C. P73 functionally replaces p53 in Adriamycin-treated, p53-deficient breast cancer cells. Int. J. Cancer 116 (2005) 860-869
29. Agami R., Blandino G., Oren M., and Shaul Y. Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis. Nature (1999) 809-813
30. Gong J.G., Costanzo A., Yang H.Q., Melino G., Kaelin Jr. W.G., Levrero M., and Wang J.Y. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 399 (1999) 806-809
31. Yuan Z.M., Shioya H., Ishiko T., Sun X., Gu J., Huang Y.Y., Lu H., Kharbanda S., Weichselbaum R., and Kufe D. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature 399 (1999) 814-817
32. Byun D.S., Chae K.S., Ryu B.K., Lee M.G., and Chi S.G. Expression and mutation analyses of P53R2, a newly identified p53 target for DNA repair in human gastric carcinoma. Int. J. Cancer 98 (2002) 718-723
33. Devlin H.L., Mack P.C., Burich R.A., Gumerlock P.H., Kung H.J., Mudryj M., and deVere White R.W. Impairment of the DNA repair and growth arrest pathways by p53R2 silencing enhances DNA damage-induced apoptosis in a p53-dependent manner in prostate cancer cells. Mol. Cancer Res. 6 (2008) 808-818
34. MacLachlan T.K., Takimoto R., and El-Deiry W.S. BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets. Mol. Cell. Biol. 22 (2002) 4280-4292
35. Xue L., Zhou B., Liu X., Heung Y., Chau J., Chu E., Li S., Jiang C., Un F., and Yen Y. Ribonucleotide reductase small subunit p53R2 facilitates p21 induction of G1 arrest under UV irradiation. Cancer Res. 67 (2007) 16-21
36. D'Orazi G., Cecchinelli B., Bruno T., Manni I., Higashimoto Y., Saito S., Gostissa M., Coen S., Marchetti A., Del Sal G., Piaggio G., Fanciulli M., Appella E., and Soddu S. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat. Cell Biol. 4 (2002) 11-19
37. Nardinocchi L., Puca R., Sacchi A., and D'Orazi G. HIPK2 knock-down compromises tumor cell efficiency to repair damaged DNA. Biochem. Biophys. Res. Commun. 361 (2007) 249-255
38. Patrone M., Percivalle E., Secchi M., Fiorina L., Pedrali-Noy G., Zoppe M., Baldanti F., Hahn G., Koszinowski U.H., Milanesi G., and Gallina A. The human cytomegalovirus UL45 gene product is a late, virion-associated protein and influences virus growth at low multiplicities of infection. J. Gen. Virol. 84 (2003) 3359-3370
39. Ye Z., and Parry J.M. The discovery and confirmation of single nucleotide polymorphisms in the human p53R2 gene by EST database analysis. Mutagenesis 17 (2002) 361-364
40. Mansson E., Flordal E., Liliemark J., Spasokoukotskaja T., Elford H., Lagercrantz S., Eriksson S., and Albertioni F. Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance. Biochem. Pharmacol. 65 (2003) 237-247
41. Smeds J., Berggren P., Ma X., Xu Z., Hemminki K., and Kumar R. Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A (p16(INK4a) and p14(ARF)) and p53 genes are major targets for inactivation. Carcinogenesis 23 (2002) 645-655
42. Smeds J., Nava M., Kumar R., and Hemminki K. A novel polymorphism (-88 C > A) in the 5′ UTR of the p53R2 gene. Hum. Mutat. 17 (2001) 82
43. Smeds J., Kumar R., and Hemminki K. Polymorphic insertion of additional repeat within an area of direct 8 bp tandem repeats in the 5′-untranslated region of the p53R2 gene and cancer risk. Mutagenesis 16 (2001) 547-550
44. Deng Z.L., Xie D.W., Bostick R.M., Miao X.J., Gong Y.L., Zhang J.H., and Wargovich M.J. Novel genetic variations of the p53R2 gene in patients with colorectal adenoma and controls. World J. Gastroenterol. 11 (2005) 5169-5173
45. Yokomakura N., Natsugoe S., Okumura H., Ikeda R., Uchikado Y., Mataki Y., Takatori H., Matsumoto M., Owaki T., Ishigami S., and Aikou T. Improvement in radiosensitivity using small interfering RNA targeting p53R2 in esophageal squamous cell carcinoma. Oncol. Rep. 18 (2007) 561-567
46. Guittet O., Tebbi A., Cottet M.-H., Vésin F., and Lepoivre M. Upregulation of the p53R2 ribonucleotide reductase subunit by nitric oxide. Nitric Oxide 19 (2008) 84-94
47. Lin Z.P., Belcourt M.F., Cory J.G., and Sartorelli A.C. Stable suppression of the R2 subunit of ribonucleotide reductase by R2-targeted short interference RNA sensitizes p53(-/-) HCT-116 colon cancer cells to DNA-damaging agents and ribonucleotide reductase inhibitors. J. Biol. Chem. 279 (2004) 27030-27038
48. Shao J., Zhou B., Zhu L., Bilio A.J., Su L., Yuan Y.C., Ren S., Lien E.J., Shih J., and Yen Y. Determination of the potency and subunit-selectivity of ribonucleotide reductase inhibitors with a recombinant-holoenzyme-based in vitro assay. Biochem. Pharmacol. 69 (2005) 627-634
49. Shao J., Zhou B., Di Bilio A.J., Zhu L., Wang T., Qi C., Shih J., and Yen Y. A ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase. Mol. Cancer Ther. 5 (2006) 586-592
50. Davidson J.D., Ma L., Flagella M., Geeganage S., Gelbert L.M., and Slapak C.A. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res. 64 (2004) 3761-3766
51. Yoshida T., Haga S., Numata Y., Yamashita K., Mikami T., Ogawa T., Ohkusa T., and Okayasu I. Disruption of the p53-p53r2 DNA repair system in ulcerative colitis contributes to colon tumorigenesis. Int. J. Cancer 118 (2006) 1395-1403
52. Hayashi H., Furihata M., Kuwahara M., Kagawa S., Shuin T., and Ohtsuki Y. Infrequent alteration in the p53R2 gene in human transitional cell carcinoma of the urinary tract. Pathobiology 71 (2004) 103-106
53. Ceballos E., Munoz-Alonso M.J., Berwanger B., Acosta J.C., Hernandez R., Krause M., Hartmann O., Eilers M., and Leon J. Inhibitory effect of c-Myc on p53-induced apoptosis in leukemia cells. Microarray analysis reveals defective induction of p53 target genes and upregulation of chaperone genes. Oncogene 24 (2005) 4559-4571
54. Okumura H., Natsugoe S., Yokomakura N., Kita Y., Matsumoto M., Uchikado Y., Setoyama T., Owaki T., Ishigami S., and Aikou T. Expression of p53R2 is related to prognosis in patients with esophageal squamous cell carcinoma. Clin. Cancer Res. 12 (2006) 3740-3745
55. Liu X., Zhou B., Xue L., Yen F., Chu P., Un F., and Yen Y. Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer. Clin. Colorectal Cancer 6 (2007) 374-381
56. Liu X., Zhou B., Xue L., Shih J., Tye K., Lin W., Qi C., Chu P., Un F., Wen W., and Yen Y. Metastasis-suppressing potential of ribonucleotide reductase small subunit p53R2 in human cancer cells. Clin. Cancer Res. 12 (2006) 6337-6344
57. Okumura H., Natsugoe S., Matsumoto M., Mataki Y., Takatori H., Ishigami S., Takao S., and Aikou T. The predictive value of p53, p53R2, and p21 for the effect of chemoradiation therapy on oesophageal squamous cell carcinoma. Br. J. Cancer 92 (2005) 284-289
58. Shao J., Zhou B., Chu B., and Yen Y. Ribonucleotide reductase inhibitors and future drug design. Curr. Cancer Drug Targets 6 (2006) 409-431
59. Ohno K., Tanaka-Azuma Y., Yoneda Y., and Yamada T. Genotoxicity test system based on p53R2 gene expression in human cells: examination with 80 chemicals. Mutat. Res. 588 (2005) 47-57